The estimated Net Worth of Daniel L Menichella is at least $599 mil dollars as of 8 February 2021. Mr Menichella owns over 20,000 units of Kaleido Biosciences Inc stock worth over $2 and over the last 11 years he sold KLDO stock worth over $0. In addition, he makes $598,722 as Pres e CEO & Director at Kaleido Biosciences Inc.
Sign up
Mr A KLDO stock SEC Form 4 insiders trading
Mr has made over 3 trades of the Kaleido Biosciences Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of KLDO stock worth $230,000 on 8 February 2021.
The largest trade he's ever made was buying 20,000 units of Kaleido Biosciences Inc stock on 8 February 2021 worth over $230,000. On average, Mr trades about 3,875 units every 280 days since 2014. As of 8 February 2021 he still owns at least 20,000 units of Kaleido Biosciences Inc stock.
You can see the complete history of Mr Menichella stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Daniel L. Menichella B.A., M.B.A. biography
Daniel L. Menichella B.A., M.B.A. is the Pres, CEO & Director at Kaleido Biosciences Inc.
What is the salary of Mr A?
As the Pres e CEO & Director of Kaleido Biosciences Inc, the total compensation of Mr A at Kaleido Biosciences Inc is $598,722. There are 3 executives at Kaleido Biosciences Inc getting paid more, with Jerald Korn having the highest compensation of $1,505,420.
How old is Mr A?
Mr A is 62, he's been the Pres e CEO & Director of Kaleido Biosciences Inc since . There are no older and 16 younger executives at Kaleido Biosciences Inc.
What's Mr A's mailing address?
Daniel's mailing address filed with the SEC is C/O KALEIDO BIOSCIENCES, 65 HAYDEN AVENUE, LEXINGTON, MA, 02421.
Insiders trading at Kaleido Biosciences Inc
Over the last 6 years, insiders at Kaleido Biosciences Inc have traded over $0 worth of Kaleido Biosciences Inc stock and bought 3,273,186 units worth $32,952,342 . The most active insiders traders include Ventures Fund Iv General Pa..., Joshua T Brumm, eVentures Fund V General Par.... On average, Kaleido Biosciences Inc executives and independent directors trade stock every 119 days with the average trade being worth of $55. The most recent stock trade was executed by Daniel L Menichella on 8 February 2021, trading 20,000 units of KLDO stock currently worth $230,000.
What does Kaleido Biosciences Inc do?
the next breakthrough microbiome company from flagship venturelabs – the innovation foundry of flagship ventures – is coming.
What does Kaleido Biosciences Inc's logo look like?
Complete history of Mr Menichella stock trades at Applied Genetic Technologies Corp e Kaleido Biosciences Inc
Kaleido Biosciences Inc executives and stock owners
Kaleido Biosciences Inc executives and other stock owners filed with the SEC include:
-
Jerald Korn,
General Counsel, Corporate Secretary -
Katharine Knobil,
Chief Medical Officer and Head of Research and Development -
William E. Duke Jr.,
Chief Financial Officer -
Daniel L. Menichella B.A., M.B.A.,
Pres, CEO & Director -
Jean Mixer,
Independent Director -
Theo Melas-Kyriazi,
Independent Director -
Michael Bonney,
Chairman of the Board -
Anthony Quinn,
Independent Director -
Grady Burnett,
Independent Director -
Bonnie Bassler,
Independent Director -
Anne Prener,
Independent Director -
William Duke,
Chief Financial Officer -
Daniel Menichella,
President, Chief Executive Officer, Principal Executive Officer -
Dr. Alison Long M.D., Ph.D.,
Chief Medical Officer -
Dr. Mark A. Wingertzahn Ph.D.,
Sr. VP of R&D and Head of Devel. -
Susan Stewart J.D.,
Chief Regulatory Affairs  Advisor -
Dr. Johan Van Hylckama Vlieg Ph.D.,
Chief Scientific Officer -
Kimberly Hocknell,
Sr. VP of Technical Operations -
Jerald Korn J.D.,
COO, Gen. Counsel & Corp. Sec. -
Dr. Geoffrey von Maltzahn Ph.D.,
Co-Founder & Director -
Hylckama Vlieg Johan Van,
Chief Scientific Officer -
Ventures Fund Iv General Pa...,
-
Joshua T Brumm,
See Remarks -
Alison Frances Lawton,
See Remarks -
Maltzahn Geoffrey Von,
Director -
Ventures Fund V General Par...,
-
Ventures Fund Iv General Pa...,
-
Ventures Fund Iv General Pa...,
-
Alison S Long,
Chief Medical Officer